Telomir Pharmaceuticals Unveils Copper Binding Breakthrough in Telomir-1

Telomir Pharmaceuticals, Inc. announced a significant advancement with Telomir-1's copper binding capabilities, positioning it as potential therapy for Wilson's disease. This condition lacks effective treatments and is characterized by toxic copper accumulation, causing severe organ damage. Current therapies, like chelating agents and zinc, bear significant side effects. Telomir-1's unique copper binding profile could present a promising alternative by addressing disease root causes.

Telomir is progressing with studies to assess Telomir-1's impact on copper regulation. The company's research pipeline also explores treatments for type 2 diabetes, cancer, and Alzheimer's, showcasing Telomir-1's broad therapeutic potential. Clinical trials are expected to commence in 2026, following IND application in 2025.

This development aligns with the rapid growth in the anti-aging market, driven by demand for therapies targeting age-related conditions. Telomir Pharmaceuticals is on track to redefine patient care with its innovative approach.